1. |
林薇, 汤善宏, 曾维政, 等. 恶性肿瘤患者并发结核感染的风险研究. 国际检验医学杂志, 2017, 38(24): 3415-3417.
|
2. |
Akbulut S, Sogutcu N, Yagmur Y. Coexistence of breast cancer and tuberculosis in axillary lymph nodes: a case report and literature review. Breast Cancer Res Treat, 2011, 130(3): 1037-1042.
|
3. |
Bromberg SE, Amaral PG. Tuberculosis axillary lymph node coexistent breast cancer in adjuvant treatment: case report. Einstein (Sao Paulo), 2015, 13(3): 423-425.
|
4. |
Pujani M, Khan S, Hassan MJ, et al. Coexistence of metastatic breast carcinoma and primary tuberculosis in axillary lymph nodes: a report of a rare case. Breast Dis, 2015, 35(3): 195-198.
|
5. |
Baslaim MM, Al-Amoudi SA, Al-Ghamdi MA, et al. Case report: breast cancer associated with contralateral tuberculosis of axillary lymph nodes. World J Surg Oncol, 2013, 11: 43. doi: 10.1186/1477-7819-11-43.
|
6. |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2020. 北京: 人民卫生出版社, 2020.
|
7. |
Vriens BEPJ, Vriens IJH, Aarts MJB, et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Res Treat, 2017, 165(3): 593-600.
|
8. |
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17(6): 791-800.
|
9. |
Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol, 2020, 6(3): e193692. doi: 10.1001/jamaoncol.2019.3692.
|
10. |
Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol, 2018, 29(7): 1497-1508.
|
11. |
中国乳腺癌新辅助治疗专家组. 中国乳腺癌新辅助治疗专家共识(2019年版). 中国癌症杂志, 2019, 29(5): 390-400.
|